Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)
 
 • Company Description   
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Number of Employees: 78

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.19 Daily Weekly Monthly
20 Day Moving Average: 358,912 shares
Shares Outstanding: 19.79 (millions)
Market Capitalization: $221.47 (millions)
Beta: 0.95
52 Week High: $22.55
52 Week Low: $9.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.20% -7.93%
12 Week -25.55% -31.17%
Year To Date -45.04% -49.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1050 WALTHAM STREET SUITE 302
-
LEXINGTON,MA 02421
USA		 ph: 617-314-6297
fax: -		 jfrantz@kerostx.com http://www.kerostx.com
 
 • General Corporate Information   
Officers
Jasbir Seehra - Chief Executive Officer
Jean-Jacques Bienaime - Chairman
Keith Regnante - Chief Financial Officer
Nima Farzan - Director
Carl Gordon - Director

Peer Information
Keros Therapeutics, Inc. (CORR.)
Keros Therapeutics, Inc. (RSPI)
Keros Therapeutics, Inc. (CGXP)
Keros Therapeutics, Inc. (BGEN)
Keros Therapeutics, Inc. (GTBP)
Keros Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 492327101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 19.79
Most Recent Split Date: (:1)
Beta: 0.95
Market Capitalization: $221.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.62 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 36.50% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.78
Price/Cash Flow: 2.47
Price / Sales: 6.67
EPS Growth
vs. Year Ago Period: -133.43%
vs. Previous Quarter: -40.70%
Sales Growth
vs. Year Ago Period: -99.83%
vs. Previous Quarter: -4.68%
ROE
03/31/26 - -17.04
12/31/25 - 14.25
09/30/25 - 9.51
ROA
03/31/26 - -15.84
12/31/25 - 13.27
09/30/25 - 8.89
Current Ratio
03/31/26 - 22.61
12/31/25 - 15.45
09/30/25 - 29.86
Quick Ratio
03/31/26 - 22.62
12/31/25 - 15.45
09/30/25 - 29.86
Operating Margin
03/31/26 - -256.60
12/31/25 - 35.65
09/30/25 - 26.12
Net Margin
03/31/26 - -256.60
12/31/25 - 35.65
09/30/25 - 26.12
Pre-Tax Margin
03/31/26 - -272.15
12/31/25 - 37.65
09/30/25 - 28.84
Book Value
03/31/26 - 14.43
12/31/25 - 15.51
09/30/25 - 23.09
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©